Mumbai, Jan 7 (UNI) The Clinical Pharmacology Unit of GVK Biosciences (GVK BIO) received approvals from all major global regulatory bodies including USFDA, AFSAAPS, WHO and ANVISA.
The approvals open global markets to GVK BIO's clients in US, Europe and Latin American countries in addition to the domestic sector.
GVK BIO President Manni Kantipudi said, ''The approvals validate GVK BIO's high quality systems and practices.'' As a first step, GVK BIO has expanded and built a new state-of-the-art bioanalytical facility, in addition to the existing one, to cater to the growing business demands. It is also setting up its own clinical laboratory and aims for an early accreditation.
''GVK BIO aims to be a full service clinical research organisation offering services from BA/BE to Phase I through Phase IV clinical trials,'' Mr Kantipudi added.
UNI AR NM SM1355